372 related articles for article (PubMed ID: 19626037)
1. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
2. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
3. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
4. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome.
Krejsgaard T; Gjerdrum LM; Ralfkiaer E; Lauenborg B; Eriksen KW; Mathiesen AM; Bovin LF; Gniadecki R; Geisler C; Ryder LP; Zhang Q; Wasik MA; Odum N; Woetmann A
Leukemia; 2008 Dec; 22(12):2230-9. PubMed ID: 18769452
[TBL] [Abstract][Full Text] [Related]
5. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
6. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
8. Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides.
Fujimura T; Okuyama R; Ito Y; Aiba S
Br J Dermatol; 2008 Jun; 158(6):1256-63. PubMed ID: 18363755
[TBL] [Abstract][Full Text] [Related]
9. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.
Geskin LJ; Akilov OE; Kwon S; Schowalter M; Watkins S; Whiteside TL; Butterfield LH; Falo LD
Cancer Immunol Immunother; 2018 Mar; 67(3):423-434. PubMed ID: 29204699
[TBL] [Abstract][Full Text] [Related]
11. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
Wong HK
G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210
[TBL] [Abstract][Full Text] [Related]
12. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
[TBL] [Abstract][Full Text] [Related]
13. Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome.
Krejsgaard T; Odum N; Geisler C; Wasik MA; Woetmann A
Leukemia; 2012 Mar; 26(3):424-32. PubMed ID: 21904385
[TBL] [Abstract][Full Text] [Related]
14. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma.
Schlapbach C; Ochsenbein A; Kaelin U; Hassan AS; Hunger RE; Yawalkar N
J Am Acad Dermatol; 2010 Jun; 62(6):995-1004. PubMed ID: 20466174
[TBL] [Abstract][Full Text] [Related]
15. The regulatory T-cell phenotype in progressive mycosis fungoides.
Hallermann C; Schulze HJ; Neumann C; Klemke CD
G Ital Dermatol Venereol; 2008 Feb; 143(1):15-9. PubMed ID: 18833048
[TBL] [Abstract][Full Text] [Related]
16. Demonstration of circulating allergen-specific CD4+CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals.
Maggi L; Santarlasci V; Liotta F; Frosali F; Angeli R; Cosmi L; Maggi E; Romagnani S; Annunziato F
J Allergy Clin Immunol; 2007 Aug; 120(2):429-36. PubMed ID: 17604089
[TBL] [Abstract][Full Text] [Related]
17. [Mycosis fungoides and Sézary syndrome: diagnostic and prognostic relevance of cellular antigen expression].
Meissner K; Löning T; Rehpenning W
Hautarzt; 1991 Feb; 42(2):84-91. PubMed ID: 2037492
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.
Weng WK; Armstrong R; Arai S; Desmarais C; Hoppe R; Kim YH
Sci Transl Med; 2013 Dec; 5(214):214ra171. PubMed ID: 24307695
[TBL] [Abstract][Full Text] [Related]
19. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.
Gjerdrum LM; Woetmann A; Odum N; Burton CM; Rossen K; Skovgaard GL; Ryder LP; Ralfkiaer E
Leukemia; 2007 Dec; 21(12):2512-8. PubMed ID: 17713545
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging.
Feng B; Jorgensen JL; Jones D; Chen SS; Hu Y; Medeiros LJ; Wang SA
Mod Pathol; 2010 Feb; 23(2):284-95. PubMed ID: 19935642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
